Nektar

"Nektar", the San Carlos drug developer, "is exceptionally well-positioned as we enter 2009," said the company's chief executive, Howard Robin, in an Marvell offering restricted stock in exchange for underwater options offered to exchange options held by its employees with an exercise price of $12 or higher for a pro-rated number of shares of restricted stock.

SiliconBeat 2009

"Nektar", the San Carlos drug developer, "is exceptionally well-positioned as we enter 2009," said the company's chief executive, Howard Robin, in an Marvell offering restricted stock in exchange for underwater options offered to exchange options held by its employees with an exercise price of $12 or higher for a pro-rated number of shares of restricted stock.

SiliconBeat 2009

"Nektar", the San Carlos drug developer, "is exceptionally well-positioned as we enter 2009," said the company's chief executive, Howard Robin, in an DepoMed calls for early end to marketing deal with Watson Pharma on urinary tract treatment early on a promotion deal Depomed, the Menlo Park drug developer, had with Watson Pharma for marketing Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

SiliconBeat 2009

"Nektar", the San Carlos drug developer, "is exceptionally well-positioned as we enter 2009," said the company's chief executive, Howard Robin, in an DepoMed calls for early end to marketing deal with Watson Pharma on urinary tract treatment early on a promotion deal Depomed, the Menlo Park drug developer, had with Watson Pharma for marketing Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

SiliconBeat 2009

"Nektar", the San Carlos drug developer, "is exceptionally well-positioned as we enter 2009," said the company's chief executive, Howard Robin, in an DepoMed calls for early end to marketing deal with Watson Pharma on urinary tract treatment early on a promotion deal Depomed, the Menlo Park drug developer, had with Watson Pharma for marketing Depomed's extended-release formulation of ciprofloxacin for the treatment of uncomplicated urinary tract infections.

SiliconBeat 2009

Pfizer Inc. licensed an inhaled form of insulin from Nektar Therapeutics and spent heavily to bring the drug to market in 2006, only to withdraw it soon after due to its lackluster sales.

Glaxo Looks for Gene-Research Payoff on Other Drugs Jeanne Whalen 2011

The B. Nektar meadery also produces some award winners.

White House state dinner - pairing green curry shrimp with grenache - a faux pas? | Dr Vino's wine blog 2009

Late last year, drug maker Nektar Therapeutics moved from suburban San Carlos to a Mission Bay facility adjacent to Bayer, across from a set of University of California, San Francisco buildings.

A Biotech Building Boom Eliot Brown 2011

Late last year, drug maker Nektar Therapeutics moved from suburban San Carlos to a Mission Bay facility adjacent to Bayer, across from a set of University of California, San Francisco buildings.

A Biotech Building Boom Eliot Brown 2011

Nektar is located at 1505 Jarvis, Suite B. in Ferndale, MI.

Honey in the Rock weakyknee 2009